Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1663778

registered interest
date	13/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to increase access to cannabis-based medicinal products on the NHS.
tabling member constituency	Ealing Central and Acton
tabling member printed	Dr Rupa Huq
uin	201631
answer	answer is ministerial correction date of answer 19/10/2023 answer text <p>Licensed cannabis-based medicines are routinely available on the National Health Service. However, clinical guidelines from the National Institute for Health and Care Excellence demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.</p><p>Funding of unlicensed products is subject to local NHS decisions on a case-by-case basis. These decisions follow clearly developed procedures that ensure equitable distribution of funding, prioritising those medicines that have proved their safety, quality and clinical and cost effectiveness.</p><p>We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.</p> answering member constituency Colchester answering member printed Will Quince question first answered 19/10/2023 11:14:45 answering member 4423 label Biography information for Will Quince
tabling member	4511 label Biography information for Dr Rupa Huq

1309164

registered interest
date	14/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that medicinal cannabis is made available on the NHS as swiftly as possible.
tabling member constituency	Ealing Central and Acton
tabling member printed	Dr Rupa Huq
uin	181076
answer	answer is ministerial correction date of answer 19/04/2021 answer text <p>In November 2018, the law changed to allow doctors on the General Medical Council’s Specialist Register to prescribe cannabis-based product for medicinal use (CBPMs). Since then, two CBPMs - Sativex and Epidyolex have been made available for prescribing on the National Health Service, where clinically appropriate. This follows clear demonstrated evidence of their safety and clinical and cost effectiveness.</p><p>There remain concerns over the clinical and cost effectiveness of unlicensed cannabis-based products for medicinal use. To help further the evidence base, significant progress has been made to support two randomised controlled trials into early onset and genetic generalised epilepsy and to establish a national patient registry. We are also considering what further action the Government might take to widen access to unlicensed cannabis-based products.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 19/04/2021 16:24:29 answering member 4380 label Biography information for Jo Churchill previous answer version 97221 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
tabling member	4511 label Biography information for Dr Rupa Huq

1151821

registered interest
date	23/10/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress has been made on ensuring that medical cannabis containing THC is available on the NHS for patients for whom clinicians have deemed it clinically appropriate.
tabling member constituency	Ealing Central and Acton
tabling member printed	Dr Rupa Huq
uin	4348
answer	answer is ministerial correction date of answer 01/11/2019 answer text <p>The law was changed on 1 November 2018 to allow clinicians on the General Medical Council’s ‘Specialist Register’ to prescribe cannabis-based products for medicinal use, where clinically appropriate and in the best interest of patients. The Government has been clear that decisions on whether to prescribe these products must remain a clinical one.</p><p> </p><p>Following a meeting in Parliament with the families of patients seeking access to medicinal cannabis, my Rt. hon. Friend the Secretary of State for Health and Social Care asked NHS England and NHS Improvement to undertake a rapid process review into any barriers to prescribing on the National Health Service, where clinically appropriate. The review report is now published, and the Department is working closely with NHS England and NHS Improvement and other delivery partners to implement the report’s recommendations. This includes committing public funds through the National Institute for Health Research to establish clinical trials to develop the evidence base and exploring alternative studies to help children and young adults with treatment resistance epilepsy who are currently receiving cannabis-based medicines. We have also contacted all producers of cannabis-based products, known to have an interest in supplying the United Kingdom market, to encourage and support research applications to develop the evidence base further.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 4260 question first answered 01/11/2019 12:26:52 answering member 4380 label Biography information for Jo Churchill
tabling member	4511 label Biography information for Dr Rupa Huq